Loungers trading ahead of expectations as new site roll-out boosts bottom line April 26, 2024 Loungers has said it is trading ahead of expectations for the year, helped by the opening of 36 new sites.
London Stock Exchange Group boss set for payday despite take-private boom April 25, 2024 The London Stock Exchange Group was dealt a bloody nose by investors today after a chunk of its shareholders voted to reject a pay rise for chief executive David Schwimmer.
Mytilineos eyes potential dual listing in London April 25, 2024 Greek energy giant Mytilineos has said it is eyeing a potential secondary listing in London before the end of next year.
Focusrite: Music software company hits flat note as revenue falls £11m April 25, 2024 Focusrite's net debt more than doubled to £27.3m in the first half of the year, which it blamed on higher working capital levels.
Drugmaker Indivior seeks shareholder approval to move primary listing from London to New York April 25, 2024 Opioid dependence treatment maker Indivior has confirmed a plan to move its primary stock market listing from London to New York this summer in yet another blow to the capital's beleaguered bourse.
Hikma: Pharma giant starts year strong as new product sales surge in key markets April 25, 2024 In 2023, the group became the second-largest pharmaceutical company in Middle East and North Africa by sales.
WPP expects to return to growth in second-half as AI tools ‘deployed at scale’ April 25, 2024 For the full year, the company said it expected to report like-for-like revenue growth less pass-through costs of zero to one per cent.
Barclays shares hit two-year high after profit beats estimates, but investment bank struggles April 25, 2024 Barclays has reported an 11 per cent drop in profit - slightly outperforming analysts' estimates - as the boost from higher interest rates fades and its investment bank struggles to compete with its Wall Street rivals.
Astrazeneca’s revenue surges as pipeline investments pay off April 25, 2024 Pascal Soriot, chief executive officer of AstraZeneca, said: "Astrazeneca had a very strong start in 2024 with substantial total revenue growth of 19 per cent in the first quarter.
Abrdn records rebound in flows as boss says cost-cutting is ‘on track’ April 24, 2024 Money manager Abrdn said its cost-cutting programme was “on track” today as its total funds under management ticked up in the first three months of the year ann the flow of cash into the firm rebounded.